1 / 1

0 5 10 0 5 10

Supplementary Fig. GST. Addition. rANX II. Cisplatin ( m M ). 0 5 10 0 5 10. Bcl-xL. Bax. Actin. GST. 2.5. rANX II. 2.0. 1.5. Relatieve amount (Bcl-xL/Bax). 1.0. 0.5. 0. 0. 10. 5. Cisplatin ( m M).

hanne
Download Presentation

0 5 10 0 5 10

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Fig. GST Addition rANX II Cisplatin(mM) 0 5 10 0 5 10 Bcl-xL Bax Actin GST 2.5 rANX II 2.0 1.5 Relatieve amount (Bcl-xL/Bax) 1.0 0.5 0 0 10 5 Cisplatin (mM) Supplementary Fig. Expression of Bcl-xL and Bax proteins following cisplatin treatment in rANX II-supplemented AsPC-1 cells. AsPC-1 cells were cultured in the presence of rANX II (0.8 µg/mL) and GST (0.027 µg/mL) for 24 h, and then treated with cisplatin at the indicated concentration. Whole cell lysates were prepared, and the expression levels of Bcl-xL, Bax, and actin proteins were analyzed by immunoblotting as described in Materials and Methods. Results depicted in the figure are representative of findings from three independent experiments. Protein levels of Bcl-xL and Bax were normalized to actin levels, and ratios of Bcl-xL to Bax levels are presented as relative values to those of control cells without cisplatin treatment (GST alone). Data are presented as mean ± SD.

More Related